Published in Blood on September 06, 2013
Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol (2015) 1.52
von Willebrand factor is a cofactor in complement regulation. Blood (2014) 1.44
Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation. Blood (2017) 1.39
Complement in disease: a defence system turning offensive. Nat Rev Nephrol (2016) 0.97
Regulatory components of the alternative complement pathway in endothelial cell cytoplasm, factor H and factor I, are not packaged in Weibel-Palade bodies. PLoS One (2015) 0.78
Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci (2016) 0.75
The effect of shiga toxin on weibel-palade bodies in primary human endothelial cells. Nephron Extra (2014) 0.75
A C3(H20) recycling pathway is a component of the intracellular complement system. J Clin Invest (2017) 0.75
Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity. Front Microbiol (2017) 0.75
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med (2014) 5.33
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int (2012) 3.99
Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet (2010) 3.74
Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 3.35
Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet (2006) 3.24
C3 glomerulopathy: a new classification. Nat Rev Nephrol (2010) 3.17
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2004) 2.97
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet (2013) 2.91
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 2.62
Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol (2004) 2.56
Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol (2004) 2.46
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 2.33
Monkey malaria in a European traveler returning from Malaysia. Emerg Infect Dis (2008) 2.32
Review of cases with the emerging fifth human malaria parasite, Plasmodium knowlesi. Clin Infect Dis (2011) 2.14
Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol (2007) 2.00
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol (2015) 1.98
A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur J Immunol (2003) 1.77
Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein. J Immunol (2007) 1.74
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat (2007) 1.59
Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A (2011) 1.58
Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol (2007) 1.57
Complement resistance mechanisms of streptococci. Mol Immunol (2003) 1.56
Transition towards antigen-binding promiscuity of a monospecific antibody. Mol Immunol (2006) 1.54
Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol (2010) 1.53
Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood (2010) 1.53
A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol (2011) 1.51
De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat (2006) 1.46
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood (2002) 1.46
Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods (2011) 1.46
C1q and its growing family. Immunobiology (2006) 1.40
New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol (2010) 1.36
Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood (2005) 1.33
Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J Immunol (2002) 1.32
Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol (2011) 1.31
Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood (2010) 1.31
Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol (2009) 1.30
Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood (2004) 1.30
Metrics: journal's impact factor skewed by a single paper. Nature (2010) 1.29
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood (2012) 1.28
Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A (2004) 1.24
Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J Immunol (2008) 1.23
Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol (2007) 1.23
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) (2004) 1.21
Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem (2009) 1.21
Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol (2010) 1.20
Lysine-dependent multipoint binding of the Borrelia burgdorferi virulence factor outer surface protein E to the C terminus of factor H. J Immunol (2004) 1.20
VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood (2006) 1.20
Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood (2013) 1.17
High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant (2006) 1.17
Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci (2009) 1.16
Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci (2004) 1.13
Comparison of surface recognition and C3b binding properties of mouse and human complement factor H. Mol Immunol (2005) 1.10
Species-specific interaction of Streptococcus pneumoniae with human complement factor H. J Immunol (2008) 1.08
Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood (2008) 1.06
Atypical haemolytic uraemic syndrome and mutations in complement regulator genes. Springer Semin Immunopathol (2005) 1.05
Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood (2008) 1.05
Complement factor H related proteins (CFHRs). Mol Immunol (2013) 1.04
Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS (2009) 1.03
A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol (2008) 1.03
Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfus Apher Sci (2007) 1.01
LPS-induced galectin-3 oligomerization results in enhancement of neutrophil activation. PLoS One (2011) 1.01
Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum Pathol (2011) 1.00
Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis (2011) 1.00
Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J Clin Immunol (2010) 1.00
Localization of the third heparin-binding site in the human complement regulator factor H1. Mol Immunol (2005) 1.00
The antiinflammatory IgG. N Engl J Med (2008) 1.00
Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. Am J Kidney Dis (2008) 0.99
Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation. Am J Kidney Dis (2005) 0.99
Complement analysis in the 21st century. Mol Immunol (2007) 0.98
Complement factor H as a marker for detection of bladder cancer. Clin Chem (2005) 0.98
Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. J Biol Chem (2005) 0.98
C3 glomerulopathy. Contrib Nephrol (2013) 0.98
Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol (2005) 0.98
The group B streptococcal beta and pneumococcal Hic proteins are structurally related immune evasion molecules that bind the complement inhibitor factor H in an analogous fashion. J Immunol (2004) 0.97
Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination. Drug Discov Today (2011) 0.97
Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance. J Immunol (2011) 0.97
Interdomain contact regions and angles between adjacent short consensus repeat domains. J Mol Biol (2004) 0.97
Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis (2010) 0.97
Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions. J Biol Chem (2007) 0.97
Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev (2008) 0.96